Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

Relief over a US-EU trade deal today benefited the FTSE 100 index in a session when leading European benchmarks rose by as ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are ... which is more than double the S&P 500's performance over the same time frame. However, the ...

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

GSK is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.52; value investors should ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...